

**Date: 15<sup>th</sup> July, 2024**

To,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers,  
Dalal Street,  
Mumbai-400 001

**Scrip Code: 524604**

Dear Sir/Madam,

**Sub.: Outcome of Board of Directors Meeting of Adline Chem Lab Limited ("the Company")**

Dear Sir/ Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, July 15<sup>th</sup>, 2024 at Registered Office of the Company has inter alia discussed following Agendas:

- (1) Considered and approved the Unaudited Financial Results along with Limited Review Report of the Company for the Quarter ended June 30<sup>th</sup>, 2024 (**Enclosed herewith**);
- (2) Approved the appointment of M/s. Rahul Doshi & Co, Chartered Accountants (**FRN: 127378W, Mem No: 117160**) as Internal Auditor of the Company;
- (3) With reference to earlier outcome submitted for Board Meeting held on 3<sup>rd</sup> February, 2024, Board Members considered and approved appointment of **M/s. Jay Pandya & Associates, Company Secretary (Firm Registration No.: S2024GJ963300)** as a Secretarial Auditor of the Company for Financial Year 2023-24 in place of M/s. Gaurav Bachani & Associates, Company Secretaries (FRN: S2020GJ718800).

The meeting of Board of Directors of the Company commenced at 04:30 P.M. and concluded at 04:50 P.M.

You are requested to kindly take the same on record and acknowledge.

**Yours faithfully,**

Thanking You,

**For, Adline Chem Lab Limited**

---

**Ritu Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A24934**  
**Encl: as above**

CIN : L24231GJ1988PLC010956

**ADLINE CHEM LAB LIMITED** (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.  
Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com

Deepak Soni & Associates

Chartered Accountants

5, Jayshree Apartments, Udhyan Marg, Nr. Law Garden, Ahmedabad – 380 006  
Phone (M) 9428246619

LIMITED REVIEW REPORT

Review Report to the Board of Directors of **ADLINE CHEM LAB LIMITED**

We have reviewed the accompanying statement of unaudited standards financial results of Adline Chem Lab Limited for the quarter ended 30<sup>th</sup> June, 2024 ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

These Statements, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statements in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of materials misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed or that it contains any material misstatement.

FOR DEEPAK SONI & ASSOCIATES  
CHARTERED ACCOUTNATNS  
FRN: 102250W



DEEPAK SONI

(Proprietor)

M.No. 031138

UDIN: 24031138BKFSK6229

PLACE: AHMEDABAD

DATE: 15<sup>TH</sup> JULY, 2024



## ADLINE CHEMLAB LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24231GJ1988PLC010956

Ph.no.: 079-26870952/54 Email Id: secretarial.adlinechemlab@gmail.com Website : www.adlinechem.com

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024.

(Rs. in Lacs except per share data)

	Particulars	Quarter Ended		Year Ended	
		30/06/2024	31/03/2024	30/06/2023	31/03/2024
		Unaudited	Audited	Unaudited	Audited
1	<b>Income from Operations</b>				
	(a) Revenue from operations	0.00	0.00	0.00	0.00
	(b) Other Income	0.00	2.66	0.00	3.13
	<b>Total Income</b>	<b>0.00</b>	<b>2.66</b>	<b>0.00</b>	<b>3.13</b>
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	3.58	1.14	1.70	4.23
	(e) Finance Cost	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00
	(g) Other expenses	6.55	5.12	6.48	13.49
	<b>Total Expenses</b>	<b>10.13</b>	<b>6.26</b>	<b>8.18</b>	<b>17.72</b>
3	<b>Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>-10.13</b>	<b>-3.60</b>	<b>-8.18</b>	<b>-14.59</b>
4	Exceptional Items	0.00	0.00	0.00	0.00
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>-10.13</b>	<b>-3.60</b>	<b>-8.18</b>	<b>-14.59</b>
6	<b>Tax Expense</b>				
	(a) Current tax	0.00	0.00	0.00	0.00
	(b) Deferred tax	0.00	0.00	0.00	0.00
	(c) Earlier year				0.07
	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.07</b>
7	<b>Profit / (Loss) for the period from continuing operations (5-6)</b>	<b>-10.13</b>	<b>-3.60</b>	<b>-8.18</b>	<b>-14.66</b>
8	<b>Profit (Loss) from discontinuing operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
9	<b>Tax Expense of discontinuing operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
10	<b>Profit (Loss) from discontinuing operations (after tax)(8-9)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
11	<b>Other Comprehensive Income</b>				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	<b>Other Comprehensive Income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
12	<b>Total Comprehensive Income for the period</b>	<b>-10.13</b>	<b>-3.60</b>	<b>-8.18</b>	<b>-14.66</b>
13	<b>Paid-up equity share capital (Face value of Rs. 10/- each)</b>	<b>585</b>	<b>585</b>	<b>585</b>	<b>585</b>
14	<b>Other Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-741.85</b>
15	<b>Earnings Per Share (before extraordinary items) (not annualised):</b>				
	(a) Basic	-0.17	-0.06	-0.14	-0.25
	(b) Diluted	-0.17	-0.06	-0.14	-0.25
16	<b>Earnings Per Share (after extraordinary items) (not annualised):</b>				
	(a) Basic	-0.17	-0.06	-0.14	-0.25
	(b) Diluted	-0.17	-0.06	-0.14	-0.25

**Notes:**

1. The above standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on July 15, 2024. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter ended June 30, 2024.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. Currently the Company has Nill Business, the new management pursuant to takeover as approved by BSE shall commence it's existing Pharma Business.

Date : 15.07.2024  
Place : Ahmedabad



For, ADLINE CHEMLAB LIMITED

*[Signature]*

SARANG BHARATBHAI PATHAK  
MANAGING DIRECTOR  
DIN:02663344